Geneoscopy

St. Louis, United States Founded: 2015 • Age: 11 yrs
Non-invasive biomarker tests for colorectal cancer are developed.
Annual revenue - Latest available
Total funding $218.9M 6 rounds
Employees - Tracked headcount
Investors 17 Known backers
Products 2 Services tracked
Competitors 9 Brand Intelligence

About Geneoscopy

Geneoscopy is a company based in St. Louis (United States) founded in 2015. Geneoscopy has raised $218.95 million across 6 funding rounds from investors including LabCorp, Mercy Health and Bio Rad. Geneoscopy offers products and services including seRNA Technology Platform and Stool-based Screening Test. Geneoscopy operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.

  • Headquarter St. Louis, United States
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Geneoscopy Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $218.95 M (USD)

    in 6 rounds

  • Latest Funding Round
    $105 M (USD), Series C

    Jan 08, 2025

  • Investors
    LabCorp

    & 16 more

  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Geneoscopy

Geneoscopy offers a comprehensive portfolio of products and services, including seRNA Technology Platform and Stool-based Screening Test.

Product name locked
Category locked
Primary

Noninvasive platform for detecting colorectal cancer and GI diseases

Product name locked
Category locked
Locked

Test for early detection of gastrointestinal conditions using RNA analysis

People of Geneoscopy

Headcount 10-50
Employee Profiles 30
Board Members and Advisors 4
Employee Profiles
People
Julie LaRocca
Svp, Quality Assurance & Regulatory Affairs
People
Erica Barnell
Chief Science Officer & Co-Founder
People
Gary Gallimore
VP, Software Engineering & Information Technology
People
Ismail Adiputra
Software QA Engineer

Unlock access to complete

Board Members and Advisors
people
James Merselis
Board Member
people
Bobby W. Sandage Jr.
Board Member
people
Drew Dennison
Board Member
people
Najeeb Thomas
Board Member

Unlock access to complete

Funding Insights of Geneoscopy

Geneoscopy has successfully raised a total of $218.95M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $105 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Geneoscopy

Geneoscopy has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include LabCorp, Mercy Health and Bio Rad.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Petrichor is engaged in supporting healthcare innovation through investments.
Locked Locked Locked
Multiple sectors are invested in by Morningside, a VC fund.
Locked Locked Locked
Venture capital fund focused on early-stage life science companies
Locked Locked Locked
Premium access

Investor details for Geneoscopy

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Geneoscopy

Investments
Premium access

Investment portfolio details for Geneoscopy

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Geneoscopy

Premium access

Detailed financials for Geneoscopy

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Geneoscopy Comparisons

Geneoscopy Primary company
Description
Non-invasive biomarker tests for colorectal cancer are devel...
Location
St. Louis, United States
Founded Year
2015
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Geneoscopy

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Geneoscopy

Geneoscopy operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
Locked Locked Locked
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
Locked Locked Locked
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
Locked Locked Locked
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
Locked Locked Locked
Genomic sequencing and diagnosis software is provided for healthcare.
Locked Locked Locked
Therapeutics for aging diseases are developed by targeting senescent cells.
Premium access

Detailed competitors of Geneoscopy

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Geneoscopy

Premium access

Complete news archive for Geneoscopy

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Geneoscopy

Geneoscopy was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Geneoscopy is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.

Geneoscopy is a funded company, having raised a total of $218.95M across 6 funding rounds to date.

Geneoscopy was founded in 2015 and is headquartered in St. Louis, United States. Non-invasive diagnostic tests for colorectal cancer are developed within the biotechnology sector. Stool samples are examined for a panel of mRNA biomarkers through a proprietary algorithm to identify the disease. The primary assay is designed for screening patients potentially needing colonoscopy procedures, with operations centered on advancing biomarker-based diagnostics.

Geneoscopy's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.

Geneoscopy offers seRNA Technology Platform and Stool-based Screening Test.

Geneoscopy has 17 investors. Key investors include LabCorp, Mercy Health, Bio Rad, Arch Grants, and Petrichor.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available